The recent emergence of Candida auris cases in Portugal reinforces the importance of effective laboratory solutions for its detection and surveillance.
The first cases of Candida auris infection were recently identified in Portugal, in a study led by the Faculty of Medicine of the University of Porto (FMUP), underlining the need for robust laboratory strategies for the detection and monitoring of this emerging fungus.
With the aim of supporting clinical laboratories, Quilaban provides a PCR kit developed by our partner Bioeksen, designed for the identification of Candida auris and other clinically relevant species, such as Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei and Candida parapsilosis.
The kit features high sensitivity and specificity, is compatible with more than ten PCR platforms and integrates easily into existing laboratory workflows. The speed in obtaining results contributes to epidemiological surveillance and to the timely implementation of infection control measures.
Candida auris is considered by the World Health Organisation a critical threat to global public health, due to its resistance to multiple antifungals, ability to persist on surfaces and ease of transmission in healthcare settings. The European Centre for Disease Prevention and Control (ECDC) has warned of the increase in cases in Europe and the need to strengthen identification and monitoring strategies.
Bioeksen products are in vitro diagnostic medical devices for professional use only. For safe use, carefully read the labelling and instructions for use.